Home › Head and Neck Squamous Cell Carcinoma › North Carolina
Head and Neck Squamous Cell Carcinoma clinical trials in North Carolina
27 studies for Head and Neck Squamous Cell Carcinoma are looking for participants at sites in North Carolina.
Cities in North Carolina
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- Site#0118, Durham
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06788990Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #12, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05176483Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Margaret R Pardee Memorial Hospital, Hendersonville
- FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06589804Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
- Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center, Huntersville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07360314A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
- Carolina Cancer Research Center, Wilson
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07276399A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
- University of North Carolina at Chapel Hill, Chapel Hill
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06385080BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Southeastern Medical Oncology Center-Clinton, Clinton
- Southeastern Medical Oncology Center-Goldsboro, Goldsboro
- Southeastern Medical Oncology Center-Jacksonville, Jacksonville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05136196JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
- University of North Carolina at Chapel Hill, Chapel Hill
- Atrium Health Levine Cancer Institute, Charlotte
RecruitingPhase 3
Ages 60 and older · All sexes · Updated Sep 25, 2026 · NCT04892173A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
- University of North Carolina at Chapel Hill, Chapel Hill
RecruitingPhase 1
Ages 18 to 74 · All sexes · Updated Sep 25, 2026 · NCT07219212Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Cone Health Cancer Center, Greensboro
- Annie Penn Memorial Hospital, Reidsville
RecruitingPhase 2
Ages 18 to 79 · All sexes · Updated Sep 22, 2026 · NCT04671667Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Carolina Biooncology Institute, Huntersville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT05267626ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- UNC- Chapel Hill, Chapel Hill
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT05059444Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT02734537A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
- Carolina BioOncology Institute /ID# 272380, Huntersville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT07241039Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT04333537Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
- Atrium Health Stanly/LCI-Albemarle, Albemarle
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Atrium Health Pineville/LCI-Pineville, Charlotte
- and 9 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT06532279Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 17, 2026 · NCT04375384Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Carolina BioOncology Institute, Huntersville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT06993844Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Duke Cancer Institute /ID# 276267, Durham
- Carolina BioOncology Institute /ID# 232597, Huntersville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT05005403Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- Duke Cancer Center /ID# 251975, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 4, 2026 · NCT04777994Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
- University of North Carolina at Chapel Hill, Chapel Hill
RecruitingObservational study
Ages 18 and older · All sexes · Updated Apr 28, 2026 · NCT04564989Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- Carolina BioOncology Institute, Huntersville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Feb 18, 2026 · NCT07030257A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- Duke Cancer Institute, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT06778863A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- Dren Investigational Site, Huntersville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jan 7, 2026 · NCT06999187Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy
- Duke University Medical Center, Durham
Recruiting
Ages 18 and older · All sexes · Updated Dec 11, 2025 · NCT05793151A Study of NX-1607 in Adults With Advanced Malignancies
- University of North Carolina, Chapel Hill
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2025 · NCT05107674Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- Levine Cancer Institute, Charlotte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 15, 2025 · NCT04429542From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.